India, Oct. 29 -- BioMarin Pharmaceutical Inc. (BMRN) announced an exclusive worldwide licensing agreement with GC Biopharma Corp (006280.KS) and Hanmi Pharm Co., Ltd (128940.KS). to develop and commercialize HM15421/GC1134A, an investigational long-acting enzyme replacement therapy for Fabry disease, excluding South Korea.
Fabry disease is a rare inherited disorder caused by mutations in the GLA gene, which reduce the activity of the alpha-galactosidase A (a-Gal A) enzyme.
This can lead to the accumulation of certain fatty substances in cells and cause complications affecting the kidneys, heart and nervous system.
Under the agreement, BioMarin will pay $70 million upfront. GC Biopharma and Hanmi Pharm are jointly eligible to receive up ...